共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
Sungkanuparph S Manosuthi W Kiertiburanakul S Piyavong B Chantratita W 《Current HIV research》2008,6(5):474-476
Etravirine demonstrates activity against NNRTI-resistant HIV-1 but its efficacy depends on the number of etravirine resistance-associated mutations (RAMs). This study aimed to evaluate the role of etravirine in the second regimen in a resource-limited setting. Genotype resistance assay was conducted in a cohort of HIV-infected patients who experienced virological failure from an initial NNRTI-based regimen. We focused on etravirine-RAMs previously described: V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/I/V, and G190A/S. Frequency and predicting factors for 2 etravirine-RAMs. Etravirine may have activity for using in the second regimen in most patients in resource-limited setting who fail an initial NNRTI-based regimen. Genotype testing is needed to identify this group. Some of these patients, indicated by genotype results, may be able to use etravirine plus 2 active NRTIs for second ART regimen. This strategy may be an option for patients who cannot afford or tolerate protease inhibitor. Prospective study to evaluate this strategy should be conducted in resource-limited setting. 相似文献
7.
8.
9.
10.
11.
12.
13.
14.
Wood E Hogg RS Heath KV de la Rosa R Lee N Yip B O'Shaughnessy MV Montaner JS 《AIDS (London, England)》2003,17(18):2629-2634
15.
16.
17.
18.
19.